Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa study of glatiramer acetate (MyeloXen) for treatment of multiple sclerosis in Russia

Next Previous
X
Search
Trial Profile

Phase IIa study of glatiramer acetate (MyeloXen) for treatment of multiple sclerosis in Russia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Multiple sclerosis vaccine (Primary)
  • Indications Multiple sclerosis
  • Focus First in man; Proof of concept; Therapeutic Use

    • Most Recent Events

    • 01 Apr 2016 Results published in a PJSC Pharmsynthez media release.
    • 01 Apr 2016 Status changed from active, no longer recruiting to completed, according to a PJSC Pharmsynthez media release.
    • 21 Nov 2014 Dosing of patients completed, according to a Xenetic Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top